KR100793047B1 - 평활근 세포 증식 억제제로서의 4-ｈ-1-벤조피란-4-온 유도체 - Google Patents

평활근 세포 증식 억제제로서의 4-ｈ-1-벤조피란-4-온 유도체 Download PDF

Info

Publication number
KR100793047B1
KR100793047B1 KR1020017009716A KR20017009716A KR100793047B1 KR 100793047 B1 KR100793047 B1 KR 100793047B1 KR 1020017009716 A KR1020017009716 A KR 1020017009716A KR 20017009716 A KR20017009716 A KR 20017009716A KR 100793047 B1 KR100793047 B1 KR 100793047B1
Authority
KR
South Korea
Prior art keywords
flavopyridol
smc
proliferation
smooth muscle
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020017009716A
Other languages
English (en)
Korean (ko)
Other versions
KR20010093309A (ko
Inventor
패터슨윈스턴캠벨
듀몬트제니퍼에이
Original Assignee
아벤티스 파마슈티칼스 인크.
보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아벤티스 파마슈티칼스 인크., 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 filed Critical 아벤티스 파마슈티칼스 인크.
Publication of KR20010093309A publication Critical patent/KR20010093309A/ko
Application granted granted Critical
Publication of KR100793047B1 publication Critical patent/KR100793047B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020017009716A 1999-02-01 2000-01-18 평활근 세포 증식 억제제로서의 4-ｈ-1-벤조피란-4-온 유도체 Expired - Fee Related KR100793047B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US24338099A 1999-02-01 1999-02-01
US09/243,380 1999-02-01
US09/468,665 US6399633B1 (en) 1999-02-01 1999-12-21 Use of 4-H-1-benzopryan-4-one derivatives as inhibitors of smooth muscle cell proliferation
US09/468,665 1999-12-21

Publications (2)

Publication Number Publication Date
KR20010093309A KR20010093309A (ko) 2001-10-27
KR100793047B1 true KR100793047B1 (ko) 2008-01-10

Family

ID=22918541

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020017009716A Expired - Fee Related KR100793047B1 (ko) 1999-02-01 2000-01-18 평활근 세포 증식 억제제로서의 4-ｈ-1-벤조피란-4-온 유도체

Country Status (38)

Country Link
US (1) US6399633B1 (https=)
EP (1) EP1150746B1 (https=)
JP (1) JP4755759B2 (https=)
KR (1) KR100793047B1 (https=)
CN (1) CN1219556C (https=)
AP (1) AP1469A (https=)
AR (1) AR042569A1 (https=)
AT (1) ATE275428T1 (https=)
AU (1) AU777368B2 (https=)
BG (1) BG65151B1 (https=)
BR (1) BR0007911A (https=)
CA (1) CA2360668C (https=)
CR (1) CR6448A (https=)
CZ (1) CZ300395B6 (https=)
DE (1) DE60013555T2 (https=)
DK (1) DK1150746T3 (https=)
EA (1) EA004786B1 (https=)
EE (1) EE04851B1 (https=)
ES (1) ES2226792T3 (https=)
HK (1) HK1042445B (https=)
HR (1) HRP20010521A2 (https=)
HU (1) HU229263B1 (https=)
ID (1) ID30180A (https=)
IL (1) IL144668A (https=)
ME (1) MEP10508A (https=)
NO (1) NO330512B1 (https=)
NZ (1) NZ512822A (https=)
OA (1) OA11755A (https=)
PL (1) PL197693B1 (https=)
PT (1) PT1150746E (https=)
RS (1) RS50242B (https=)
SI (1) SI1150746T1 (https=)
SK (1) SK286747B6 (https=)
TR (1) TR200102223T2 (https=)
TW (1) TWI273907B (https=)
UA (1) UA73110C2 (https=)
WO (1) WO2000044362A2 (https=)
ZA (1) ZA200105596B (https=)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0102480D0 (en) * 2001-01-31 2001-03-14 Cyclacel Ltd Marker
AU2003234733B2 (en) * 2002-04-17 2009-01-29 Cytokinetics, Inc. Compounds, compositions, and methods
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
WO2004002226A1 (en) * 2002-06-28 2004-01-08 Baylor College Of Medicine Modulators of cdk9 as a therapeutic target in cardiac hypertrophy
US20040106647A1 (en) * 2002-06-28 2004-06-03 Schneider Michael D. Modulators of Cdk9 as a therapeutic target in cardiac hypertrophy
WO2004022097A1 (en) * 2002-09-05 2004-03-18 Medimmune, Inc. Methods of preventing or treating cell malignancies by administering cd2 antagonists
US8034831B2 (en) 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
JP4764818B2 (ja) 2003-04-11 2011-09-07 メディミューン，エルエルシー 組換えｉｌ−９抗体およびその使用
US20060228350A1 (en) * 2003-08-18 2006-10-12 Medimmune, Inc. Framework-shuffling of antibodies
EP1660186B1 (en) 2003-08-18 2013-12-25 MedImmune, LLC Humanization of antibodies
US20060121042A1 (en) 2004-10-27 2006-06-08 Medimmune, Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
JP5153613B2 (ja) 2005-03-18 2013-02-27 メディミューン，エルエルシー 抗体のフレームワーク・シャッフル
EP1893647A2 (en) 2005-06-23 2008-03-05 MedImmune, Inc. Antibody formulations having optimized aggregation and fragmentation profiles
WO2007010342A1 (en) * 2005-07-15 2007-01-25 Sahajanand Biotech Private Limited Implantable medical devices comprising a flavonoid or derivative thereof for prevention of restenosis
JP2008255008A (ja) * 2005-07-19 2008-10-23 Tokyo Medical & Dental Univ 滑膜細胞増殖抑制剤
CA2617213C (en) * 2005-07-29 2014-01-28 Resverlogix Corp. Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
ES2439994T3 (es) 2006-08-28 2014-01-27 Kyowa Hakko Kirin Co., Ltd. Anticuerpos antagonistas monoclonales humanos específicos de LIGHT humano
WO2008092231A1 (en) 2007-02-01 2008-08-07 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular diseases
CA2682292A1 (en) 2007-03-30 2008-10-09 Medimmune, Llc Aqueous formulation comprising an anti-human interferon alpha antibody
KR101629356B1 (ko) 2008-06-26 2016-06-13 리스버로직스 코퍼레이션 퀴나졸리논 유도체의 제조방법
AU2010204106B2 (en) 2009-01-08 2014-05-08 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular disease
NZ755378A (en) 2009-03-18 2022-07-29 Resverlogix Corp Novel quinazolinones and related compounds for use as anti-inflammatory agents
KR20190091564A (ko) 2009-04-22 2019-08-06 리스버로직스 코퍼레이션 신규한 소염제
WO2012007327A1 (en) 2010-07-12 2012-01-19 Dkfz Deutsches Krebsforschungszentrum Wogonin for the prevention and therapy of cardiac hypertrophy
US9540443B2 (en) 2011-01-26 2017-01-10 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies
RU2640115C2 (ru) 2011-11-01 2017-12-26 Ресверлоджикс Корп. Фармацевтические композиции замещенных хиназолинонов
CN116574185A (zh) 2012-07-25 2023-08-11 塞尔德克斯医疗公司 抗kit抗体及其用途
WO2014059028A1 (en) 2012-10-09 2014-04-17 Igenica, Inc. Anti-c16orf54 antibodies and methods of use thereof
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
AU2013365926B9 (en) 2012-12-21 2019-01-17 Zenith Epigenetics Ltd. Novel heterocyclic compounds as bromodomain inhibitors
SG11201509982UA (https=) 2013-06-06 2016-04-28 Igenica Biotherapeutics Inc
KR102313341B1 (ko) 2013-08-26 2021-10-18 바이오엔테크 리서치 앤드 디벨롭먼트 인코포레이티드 시알릴-루이스 ａ에 대한 사람 항체 코드화 핵산
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
DK3154583T3 (da) 2014-06-04 2021-03-22 Biontech Res And Development Inc Humane monoklonale antistoffer mod gangliosid gd2
PL3333191T3 (pl) 2014-12-11 2021-05-04 Pierre Fabre Médicament Przeciwciała przeciwko c10orf54 i ich zastosowania
MX2017011194A (es) 2015-03-03 2018-04-10 Kymab Ltd Anticuerpos, usos y métodos.
JO3789B1 (ar) 2015-03-13 2021-01-31 Resverlogix Corp التراكيب والوسائل العلاجية المعتمدة لمعالجة الامراض المتعلقة بالمتممة
US9901574B2 (en) 2015-04-20 2018-02-27 Tolero Pharmaceuticals, Inc. Predicting response to alvocidib by mitochondrial profiling
ES2739749T3 (es) 2015-05-18 2020-02-03 Tolero Pharmaceuticals Inc Profármacos de alvocidib que tienen biodisponibilidad aumentada
MX2018001289A (es) 2015-08-03 2018-04-30 Tolero Pharmaceuticals Inc Terapias de combinacion para el tratamiento del cancer.
CN114470194A (zh) 2015-12-02 2022-05-13 斯特库伯株式会社 与btn1a1免疫特异性结合的抗体和分子及其治疗用途
KR102815803B1 (ko) 2015-12-02 2025-06-05 주식회사 에스티사이언스 당화된 btla(b- 및 t-림프구 약화인자)에 특이적인 항체
CN109803684B (zh) 2016-08-23 2022-08-23 卫材 R&D 管理有限公司 用于治疗肝细胞癌的组合疗法
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
WO2018094275A1 (en) 2016-11-18 2018-05-24 Tolero Pharmaceuticals, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
US11083722B2 (en) 2017-03-16 2021-08-10 Eisai R&D Management Co., Ltd. Combination therapies for the treatment of breast cancer
US12215151B2 (en) 2017-05-31 2025-02-04 Stcube & Co., Inc. Methods of treating cancer using antibodies and molecules that immunospecifically bind to BTN1A1
KR20200015602A (ko) 2017-05-31 2020-02-12 주식회사 에스티큐브앤컴퍼니 Btn1a1에 면역특이적으로 결합하는 항체 및 분자 및 이의 치료적 용도
CN110997724A (zh) 2017-06-06 2020-04-10 斯特库伯株式会社 使用结合btn1a1或btn1a1-配体的抗体和分子治疗癌症的方法
WO2019055579A1 (en) 2017-09-12 2019-03-21 Tolero Pharmaceuticals, Inc. TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR
US11707522B2 (en) 2017-10-13 2023-07-25 Boehringer Ingelheim International Gmbh Human antibodies to Tn antigen
KR102767692B1 (ko) 2018-07-20 2025-02-17 피에르 파브르 메디카먼트 Vista의 수용체
US11034710B2 (en) 2018-12-04 2021-06-15 Sumitomo Dainippon Pharma Oncology, Inc. CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
US11793802B2 (en) 2019-03-20 2023-10-24 Sumitomo Pharma Oncology, Inc. Treatment of acute myeloid leukemia (AML) with venetoclax failure
CN113559244B (zh) * 2021-08-02 2023-12-26 华中科技大学同济医学院附属协和医院 Ctrp13脂肪因子的新用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998013344A1 (en) * 1996-09-26 1998-04-02 Bristol-Myers Squibb Company A process for the preparation of chiral ketone intermediates useful for the preparation of flavopiridol and analogs

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN164232B (https=) * 1986-04-11 1989-02-04 Hoechst India
US5284856A (en) * 1988-10-28 1994-02-08 Hoechst Aktiengesellschaft Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives
US5733920A (en) 1995-10-31 1998-03-31 Mitotix, Inc. Inhibitors of cyclin dependent kinases
US5849733A (en) 1996-05-10 1998-12-15 Bristol-Myers Squibb Co. 2-thio or 2-oxo flavopiridol analogs
ES2301194T3 (es) 1997-02-05 2008-06-16 Warner-Lambert Company Llc Pirido 2,3-d pirimidinas y 4-aminopirimidinas como inhibidores de la proliferacion celular.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998013344A1 (en) * 1996-09-26 1998-04-02 Bristol-Myers Squibb Company A process for the preparation of chiral ketone intermediates useful for the preparation of flavopiridol and analogs

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
국제공개특허 제98/13344호

Also Published As

Publication number Publication date
ZA200105596B (en) 2002-10-07
JP4755759B2 (ja) 2011-08-24
EA200100742A1 (ru) 2001-12-24
WO2000044362A2 (en) 2000-08-03
TR200102223T2 (tr) 2004-12-21
CN1219556C (zh) 2005-09-21
AP1469A (en) 2005-09-26
DK1150746T3 (da) 2005-01-10
EA004786B1 (ru) 2004-08-26
AP2001002218A0 (en) 2001-09-30
CZ20012804A3 (cs) 2002-08-14
BG65151B1 (bg) 2007-04-30
UA73110C2 (en) 2005-06-15
PL197693B1 (pl) 2008-04-30
CN1338958A (zh) 2002-03-06
OA11755A (en) 2005-07-19
YU54401A (sh) 2004-05-12
MEP10508A (en) 2010-06-10
ID30180A (id) 2001-11-08
HRP20010521A2 (en) 2002-08-31
SI1150746T1 (en) 2005-02-28
AU3209800A (en) 2000-08-18
SK10862001A3 (sk) 2002-07-02
PT1150746E (pt) 2004-12-31
IL144668A0 (en) 2002-05-23
NO20013335L (no) 2001-09-25
BR0007911A (pt) 2001-10-16
ES2226792T3 (es) 2005-04-01
CR6448A (es) 2004-03-17
HK1042445A1 (en) 2002-08-16
AR042569A1 (es) 2005-06-29
JP2002535356A (ja) 2002-10-22
EE200100385A (et) 2002-12-16
ATE275428T1 (de) 2004-09-15
TWI273907B (en) 2007-02-21
CA2360668A1 (en) 2000-08-03
CZ300395B6 (cs) 2009-05-06
DE60013555D1 (de) 2004-10-14
HK1042445B (zh) 2006-01-13
EP1150746B1 (en) 2004-09-08
HUP0200804A3 (en) 2004-03-29
IL144668A (en) 2005-06-19
HU229263B1 (en) 2013-10-28
US6399633B1 (en) 2002-06-04
CA2360668C (en) 2009-03-17
EE04851B1 (et) 2007-06-15
KR20010093309A (ko) 2001-10-27
AU777368B2 (en) 2004-10-14
NO330512B1 (no) 2011-05-09
PL350735A1 (en) 2003-01-27
SK286747B6 (sk) 2009-04-06
WO2000044362A3 (en) 2001-04-05
NO20013335D0 (no) 2001-07-05
BG105751A (en) 2002-02-28
NZ512822A (en) 2005-01-28
RS50242B (sr) 2009-07-15
HUP0200804A2 (hu) 2002-12-28
DE60013555T2 (de) 2005-09-29
EP1150746A2 (en) 2001-11-07

Similar Documents

Publication Publication Date Title
KR100793047B1 (ko) 평활근 세포 증식 억제제로서의 4-ｈ-1-벤조피란-4-온 유도체
Zhu et al. Vinpocetine inhibits RANKL-induced osteoclastogenesis and attenuates ovariectomy-induced bone loss
Pan et al. USP20 mitigates ischemic stroke in mice by suppressing neuroinflammation and neuron death via regulating PTEN signal
US6218437B1 (en) Treatment and prevention of hepatic disorders
US6319955B1 (en) Use of MEK1 inhibitors as protective agents against damage due to ischemia
CA2504388A1 (en) Quinazolinone compositions for regulation of gene expression related to pathological processes
MXPA01007278A (en) The use of 4-h-1-benzopyran-4-one derivatives as inhibitors of smooth muscle cell proliferation
US20040048845A1 (en) Pharmaceutical compositions and methods for preventing skin tumor formation and causing regression of existing tumors
US6495588B2 (en) Scytonemin and methods of using thereof
JP2023081768A (ja) 脂肪肝治療剤、医薬組成物、治療方法、及びスクリーニング方法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

G170 Re-publication after modification of scope of protection [patent]
PG1701 Publication of correction

St.27 status event code: A-5-5-P10-P19-oth-PG1701

Patent document republication publication date: 20080421

Republication note text: Request for Correction Notice (Document Request)

Gazette number: 1007930470000

Gazette reference publication date: 20080110

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20111223

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20121226

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20140104

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20140104

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000